D. E. Shaw & Co., Inc. Esperion Therapeutics, Inc. Transaction History

D. E. Shaw & Co., Inc.

$100 Billion
Q1 2025

A detailed history of D. E. Shaw & Co., Inc. transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 275,707 shares of ESPR stock, worth $319,820. This represents 0.0% of its overall portfolio holdings.

Number of Shares

275,707

Previous 251,592 9.58%

Holding current value

$319,820

Previous $553,000 28.21%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$1.44 - $2.34 $34,725 - $56,429	24,115 Added 9.58%	275,707 $397,000
Q4 2024 Feb 14, 2025	BUY	$1.61 - $3.83 $244,750 - $582,232	152,019 Added 152.67%	251,592 $553,000
Q3 2024 Nov 14, 2024	SELL	$1.61 - $2.73 $455,493 - $772,357	-282,915 Reduced 73.97%	99,573 $164,000
Q2 2024 Aug 14, 2024	SELL	$1.84 - $3.24 $8.76 Million - $15.4 Million	-4,760,998 Reduced 92.56%	382,488 $849,000
Q1 2024 May 15, 2024	BUY	$2.02 - $3.02 $7.94 Million - $11.9 Million	3,930,283 Added 323.96%	5,143,486 $13.8 Million
Q4 2023 Feb 14, 2024	BUY	$0.73 - $3.08 $885,638 - $3.74 Million	1,213,203 New	1,213,203 $3.63 Million
Q3 2022 Nov 14, 2022	SELL	$5.45 - $8.13 $1.92 Million - $2.87 Million	-352,439 Reduced 50.1%	351,039 $2.35 Million
Q2 2022 Aug 15, 2022	BUY	$4.77 - $6.67 $315,020 - $440,500	66,042 Added 10.36%	703,478 $4.47 Million
Q1 2022 May 16, 2022	SELL	$3.34 - $5.56 $825,100 - $1.37 Million	-247,036 Reduced 27.93%	637,436 $2.96 Million
Q4 2021 Feb 14, 2022	BUY	$4.81 - $11.92 $4.14 Million - $10.3 Million	861,393 Added 3732.37%	884,472 $4.42 Million
Q3 2021 Nov 15, 2021	BUY	$11.34 - $21.37 $180,918 - $340,936	15,954 Added 223.92%	23,079 $278,000
Q1 2020 May 15, 2020	SELL	$27.44 - $73.84 $1.12 Million - $3.02 Million	-40,850 Reduced 85.15%	7,125 $225,000
Q4 2019 Feb 14, 2020	BUY	$35.4 - $59.82 $633,129 - $1.07 Million	17,885 Added 59.44%	47,975 $2.86 Million
Q3 2019 Nov 14, 2019	BUY	$34.47 - $47.53 $656,860 - $905,731	19,056 Added 172.7%	30,090 $1.1 Million
Q2 2019 Aug 14, 2019	SELL	$40.1 - $52.33 $271,196 - $353,907	-6,763 Reduced 38.0%	11,034 $514,000
Q3 2018 Nov 14, 2018	SELL	$40.74 - $51.41 $66,691 - $84,158	-1,637 Reduced 8.42%	17,797 $790,000
Q1 2018 May 15, 2018	BUY	$65.94 - $80.76 $592,009 - $725,063	8,978 Added 85.86%	19,434 $1.41 Million
Q4 2017 Feb 14, 2018	BUY	$43.47 - $67.43 $454,522 - $705,048	10,456	10,456 $688,000

Others Institutions Holding ESPR

# of Institutions

200

Shares Held

119M

Call Options Held

171K

Put Options Held

679K

View Full List

About Esperion Therapeutics, Inc.

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $77.2M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

More about ESPR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account